Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Summit Therapeutics Inc.

< Previous 1 2 Next >
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Raises $235 Million
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.